Fastest Weight Loss Velocity
Mazdutide (Innovent/Eli Lilly) is a GLP-1/Glucagon dual-agonist that has demonstrated unprecedented speed of weight reduction. In Phase II trials, participants lost up to 15.4% body weight in just 24 weeks—a milestone that took semaglutide nearly 60 weeks to achieve.
The balanced 3:1 ratio of GLP-1 to glucagon agonism gives Mazdutide its edge: powerful appetite suppression coupled with aggressive hepatic and adipose fat mobilization.
Liver Fat Clearance
Mazdutide's glucagon component targets hepatic steatosis with remarkable efficacy. Clinical data showed up to 73.3% reduction in liver fat content within 24 weeks. This positions Mazdutide as potentially the first-line pharmacotherapy for NAFLD/MASH once approved.
Side Effect Profile
Expected GI effects (nausea, vomiting) are consistent with the GLP-1 class. The glucagon agonism introduces a modest 3-5 bpm resting heart rate elevation and theoretical transient hyperglycemia risk, though the GLP-1 component's insulin-stimulating action effectively counterbalances this.
